CCS members publish new tumor suppressor function of IL6/STAT3 with implications for prostate cancer therapy in Nature Comm.

July 23, 2015

Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. In a collaborative effort, CCS members from the Kenner and Aberger lab show that inactivation of IL6/STAT3 signalling unexpectedly accelerates cancer progression leading to metastasis. Mechanistically, STAT3 directly controls the p19ARF tumor suppressor inducing senescence. STAT3 and ARF therefore representnovel  be prognostic markers to stratify high from low risk PCa patients. The findings also challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition. read the full article

Please reload

 Recommended News 

Salzburg Breast Cancer Meeting - Mastering Translational Immuno-Oncology

January 13, 2017

Please reload

 Recent News 
Please reload